Eribulin-Promomed

The drug is used to treat adult patients over 18 years of age.:

• in case of locally advanced or metastatic (spread beyond the primary tumor) breast cancer, if the therapy that was previously used proved ineffective;
• if liposarcoma is not amenable to surgical treatment (a type of cancerous tumor formed from adipose tissue), if the therapy that was previously used proved ineffective.

Like all medications, ERIBULIN-PROMOMED can cause undesirable reactions, but they do not occur in everyone.
It is important that you inform your doctor about any adverse reactions that occur so that he can take appropriate measures (for example, temporarily suspend or cancel treatment, change the dose and duration of the drug, and prescribe additional therapy).
Some adverse reactions can be serious and life-threatening. Contact your doctor immediately if you experience the following serious reactions:
Sepsis, including neutropenic sepsis and septic shock. If your body temperature rises sharply above 38 ° C and your blood pressure drops, if close people in your environment notice a violation or loss of consciousness, you should immediately seek medical help. (These reactions may occur occasionally, in no more than 1 person out of 100).
Deep vein thrombosis, including pulmonary embolism (PE). If you or your loved ones notice discoloration of the skin of your face and neck, or difficulty breathing, immediately seek help from your doctor. (These reactions may occur infrequently, in no more than 1 person out of 100).
Angioedema (Angioedema). If you notice swelling of the face, neck, tongue, difficulty breathing and swallowing, immediately seek help from your doctor. (These reactions may occur infrequently, not more than 1 in 100 people).
Disseminated intravascular coagulation of blood.
This symptom complex occurs in conjunction with sepsis, thrombosis, or bleeding.
The manifestations of this condition can be seen by your doctor based on the results of your tests. (The frequency of this reaction is unknown according to available data, as these are isolated cases).
Stevens Johnson syndrome/toxic epidermal necrolysis. If after using the drug you notice any rashes on the skin throughout the body and mucous membranes, soreness, swelling and severe itching, immediately seek help from your doctor. (The frequency of occurrence of this reaction is unknown according to available data, as these are isolated cases).

For more information about all possible adverse reactions and the frequency of their occurrence, see the instructions in the leaflet.

Do not use the drug ERIBULIN-PROMOMED:

• if you are allergic to eribulin mesylate or any other components of the drug (listed in section 6 of the leaflet);
• if you are pregnant or breastfeeding.

Tell your doctor that you are using, have recently used, or may start using any other medications.
Your doctor needs to know about the medications you are taking in order to take into account possible adverse reactions that may develop due to the interaction of various medications with ERIBULIN-PROMOMED, and possibly adjust the doses of the medications you are taking.
The effect of eribulin on other medications
When used concomitantly with medications with a narrow therapeutic range, such as alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, caution should be exercised and monitoring of one's well—being and possible adverse events.

The holder of the registration certificate
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, 430030, Republic of Mordovia
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, Republic of Mordovia, 430030
Phone: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.pro
The organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, Republic of Mordovia, 430030
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

Store at temperatures below 25 °C. Keep the bottle in the outer packaging. Do not freeze.

The drug can cause fatigue and dizziness. When these signs appear, refrain from driving or operating machinery.

The drug ERIBULIN-PROMOMED is not intended for use in children and adolescents under 18 years of age (the safety and efficacy of the drug in children under 18 years of age have not been established).